Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

Akio Kawabe  
University of Occupational and Environmental Health, Japan

Kazuhisa Nakano  
University of Occupational and Environmental Health, Japan

Satoshi Kubo  
University of Occupational and Environmental Health, Japan

Takeshi Asakawa  
University of Occupational and Environmental Health, Japan

Yoshiya Tanaka (✉ tanaka@med.uoeh-u.ac.jp)  
University of Occupation and Environmental Health, Japan  https://orcid.org/0000-0002-0807-7139

Research article

Keywords: Rheumatoid arthritis, Biological disease-modifying antirheumatic drugs, Retention rate, Inverse probability of treatment weighting, Generalized propensity score

Posted Date: April 29th, 2020

DOI: https://doi.org/10.21203/rs.2.23604/v2

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License

Version of Record: A version of this preprint was published at Arthritis Research & Therapy on June 8th, 2020. See the published version at https://doi.org/10.1186/s13075-020-02233-9.
Abstract

Background. The effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) by age group (<65, 65–74, and ≥75 years) are uncertain. We examined retention rates reflecting the effectiveness and safety of bDMARDs in actual clinical practice for clarifying optimal therapeutic strategies for rheumatoid arthritis (RA) by age groups.

Methods. Data of patients who were treated with tumor necrosis factor inhibitors (TNFi), abatacept (ABA), and tocilizumab (TCZ) between February 2011 and April 2017 were retrospectively collected from an observational registry of RA patients. A total of 1,362 patients were enrolled, of which 695 were aged <65 years, 402 were aged 65–74 years, and 265 were aged ≥75 years. Primary outcome was the drug retention rate in adjusted data using inverse probability of treatment weighting based on generalized propensity scores.

Results. In patients aged <65 years, three-year retention rates of TNFi, ABA, and TCZ were 43%, 47%, and 69%, respectively (ABA versus TCZ, p = 0.017; TNFi versus TCZ, p = 0.002). In patients aged 65–74 years, three-year retention rates of TNFi, ABA, and TCZ were 44%, 53%, and 60%, respectively (TCZ versus TNFi, p = 0.034). In patients aged ≥75 years, three-year retention rates for TNFi, ABA, and TCZ were 38%, 63%, and 58%, respectively (ABA versus TNFi, p = 0.017).

Conclusions. We found that the effectiveness and safety of TCZ were maximal in patients aged <75 years and that patients aged ≥75 years might be suitable candidates for TCZ and ABA therapy. The use of therapeutic strategies appropriate to each age group might improve the outcomes of bDMARD therapy for RA.

Background

Because the ratio of elderly people has markedly increased, therapeutic strategies in patients with elderly rheumatoid arthritis (RA) are emerging and important concerns to be addressed. Especially in Japan which is rapidly transitioning into a super-aged society, with approximately 30% in the country being at least 65 years of age [1]. Consequently, maintaining the psychosomatic health of people aged 65–74 years and encouraging them to participate in social activities are some important issues. A new definition of true elderly people as those aged ≥75 years has been proposed [2]. In such a super-aged society, patients with RA are also increasingly becoming older. Thus, Japan may be a good model for developing therapeutic strategies against RA in a super-aged society that the world will face in the future.

For RA, methotrexate (MTX) and biological disease-modifying antirheumatic drugs (bDMARDs) are key options for achieving treat-to-target goals [3]. This stands true for treating elderly RA patients. However, because elderly patients exhibit age-related decreases in activities of daily living (ADL) and organ function, the incidence of adverse events (AEs) increases inevitably [4]. Accordingly, appropriate use of bDMARDs for treating RA is more important in elderly patients than in young patients. The optimal therapeutic strategy using bDMARDs for elderly and young RA patients must be reexamined. Thus, the effectiveness and safety of bDMARDs should be compared and analyzed across age groups.

Drug retention rate reflects its effectiveness and safety [5]. In elderly patients, retention rates of individual bDMARDs and of bDMARDs by age group have been investigated [6-8]. However, there has been no comparative analysis of retention rates of bDMARDs among age groups (<65, 65–74, and ≥75 years). Moreover, observational studies on retention rates of individual drugs have predominantly been conducted in actual clinical practice; as such selection bias or confounding represent a problem for comparisons between drugs.
In this study, selection bias and confounding were reduced by applying inverse probability of treatment weighting (IPTW) based on generalized propensity score [9, 10] and retention rates of bDMARDs were compared by age groups to clarify the optimal therapeutic strategies using bDMARDs.

Methods

Patients and study design. The FIRST registry is an observational registry designed to assess the effectiveness and safety of bDMARDs in patients with RA at our institution with a maximum follow-up period of 5 years. The risks associated with the use of bDMARDs were evaluated beforehand for each patient. The objective of this registry was to clarify the optimal therapeutic strategy using bDMARDs. Registration was initiated in March 2003; in total, 3,891 patients with RA were registered until March 2020. bDMARDs included tumor necrosis factor inhibitors (TNFi) (infliximab [IFX], etanercept [ETN], adalimumab [ADA], golimumab [GLM], and certolizumab pegol [CZP]); abatacept (ABA); and tocilizumab (TCZ). Patient data were retrospectively collected from the FIRST registry.

In Japan, until January 2011, the maximum dose of MTX approved by the Ministry of Health, Labour and Welfare was 8 mg/week. Then, in February 2011, the maximum approved dose of MTX was increased to 16 mg/week for adults aged 20 years and above with RA. To avoid the effect of MTX restriction on the effectiveness and safety analysis, patients who received bDMARD therapy between March 2003 and January 2011 and who were aged less than 20 years were excluded from the analysis. In addition, patients whose data were missing were excluded. Patients who received bDMARD therapy between February 2011 and April 2017, who were aged 20 years and above, and who were followed up for at least 6 months were included in this study (Additional file 1: Figure S1).

According to the World Health Organization, most developed countries in the world have accepted the chronological age of 65 years for the definition of elderly [11]. The elderly population aged 65 years and above can be divided into three groups by age: young-old (65–74 years), middle-old (75–84 years), and oldest-old (≥85 years) [12]. In this study, we focused on a therapeutic strategy using bDMARDs in the elderly population. Especially in the elderly population aged ≥75 years, frailty—an important risk factor for impaired ADL, hospitalization, and death—increases rapidly [13, 14]. This suggests that the risk of AEs is high in elderly patients aged 75 years and above. The rate of people aged ≥75 years have recently markedly increased in the advanced countries and it is an emerging issue how these people can successfully improve their quality of life. Therefore, we performed subgroup analysis by dividing the elderly population into age groups of 65–74 years and ≥75 years, to compare the effectiveness and safety of bDMARDs among these groups.

RA was diagnosed based on the 1987 American College of Rheumatology Classification Criteria or 2010 American College of Rheumatology/European League against Rheumatism classification criteria [15-17]. The study was approved by the ethics review board of the university, and written informed consent was waived because of the retrospective study design.

bDMARD treatment. bDMARDs were prescribed to RA patients who were not adequately responsive to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) therapies. bDMARDs included both intravenous and subcutaneous agents and were administered based on the guidelines of the Japan College of Rheumatology.

Drug retention, discontinuation, and clinical effectiveness. The primary outcome was the drug retention rate in adjusted data analysis; secondary outcomes included reasons for discontinuation in non-adjusted data analysis and clinical effectiveness in non-adjusted and adjusted data analysis. Drug retention was analyzed according to the duration of treatment until drug discontinuation at the physician's judgment. Reasons for discontinuation were investigated using medical records and classified into discontinuation because of remission, effect insufficiency, AEs,
or others (patient choice, economic, unspecified cause, and so on). Regarding discontinuation because of remission, physicians judged the state of the absence of disease activity based on composite measures such as the disease activity score using 28 joint counts (DAS28), the clinical disease activity index (CDAI), or the simple or simplified disease activity index (SDAI) [18, 19]. Moreover, regarding effect insufficiency, physicians judged increase, return, or no change in disease activity based on composite measures. AEs were further classified according to Common Terminology Criteria for Adverse Events version 5.0 [20]. Because CDAI precisely reflects clinical response to bDMARDs, including TCZ [21], clinical effectiveness was evaluated as CDAI [22, 23].

Statistical analysis. In analysis of baseline characteristics, summary statistics were presented using proportions for categorical data and medians and interquartile ranges for continuous data. In analysis of reasons for bDMARDs discontinuation, summary statistics were presented using of the number of incidents and incidence. Kruskal–Wallis and chi-square tests were used to assess differences among groups. In non-adjusted data analysis, the Kaplan–Meier method was used to assess drug retention rates.

Observational studies typically involve patients who are commonly encountered in daily clinical practice; however, the study participants are subject to selection bias or confounding by indication due to the uncontrolled differences. To overcome this issue, sophisticated statistical methods are often used. Propensity score adjustment is a widely used method that attempts to control selection bias and confounding by indication in observational studies of treatment effect [24]. The propensity score matching and IPTW based on propensity score are the most popular methods applied in clinical research to reduce selection bias and confounding. However, the propensity score matching requires a number of subjects because matched patients have to be extracted from a primary study population. Also, the propensity score matching is performed for comparisons between two groups. For comparisons among multiple groups, the adjustment cannot be performed without any changes. The expanded concept of generalized propensity scores is applied to match multiple groups [9, 10]. Accordingly, in adjusted data analysis, IPTW was used based on generalized propensity scores. In this study, for covariate adjustment in the three groups of patients treated with TNFi, ABA, or TCZ, age, disease duration, gender, history of bDMARD use, MTX dose, glucocorticoid (GC) dose, tender joint count, swollen joint count, patient global assessment, evaluator global assessment, Health Assessment Questionnaire-Disability Index (HAQ-DI), C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF) level were used as baseline covariates, and generalized propensity scores were estimated using multinomial logistic regression. Area under the curve of generalized propensity scores was >0.7 for each bDMARD. Balance following covariate adjustment was examined, and covariate adjustment was confirmed. bDMARD retention rates were analyzed using the Kaplan–Meier method and p values were calculated using the Cox proportional hazards model [10]. Since the covariates including the time-dependent covariates were adjusted using IPTW based on generalized propensity scores, the proportional hazards assumption holds.

All reported p values are two-sided, and the level of significance was p < 0.05. All analyses were performed using JMP® version 13.0.0 (SAS Institute Inc., Cary, NC, USA), SPSS® version 25 (SPSS Inc., Chicago, IL, USA), or STATA® version 14.0 (StataCorp, College Station, TX, USA).

Results

Patients. Additional file 1: Figure S1 shows the flow chart of patient recruitment. In total, 2,139 RA patients were treated with bDMARDs between March 2003 and April 2017. We excluded 749 patients who were treated with bDMARDs between March 2003 and January 2011 and 5 patients who were <20 years old. We also excluded 23 patients whose data were missing. Finally, 1,362 patients who were treated with bDMARDs between February 2011
and April 2017 were retrospectively enrolled, of which 695 were <65 years old, 402 were 65–74 years old, and 265 were ≥75 years old.

**Retention rates of bDMARDs in non-adjusted data.** Table 1 summarizes characteristics of all patients and age groups. Patients aged ≥75 years exhibited higher incidence of advanced-stage RA, higher ABA and GC usage, higher pre-existing lung disease prevalence, lower MTX usage, stronger inflammatory responses (e.g., CRP and ESR), higher RF levels, higher CDAI scores, and higher HAQ-DI scores than patients aged <65 and 65–74 years.

Table 2 presents patient characteristics according to bDMARD usage. Additional file 1: Tables S1-3 present characteristics of each age group according to bDMARD usage. TNFi and TCZ usage decreased with age, whereas ABA usage remained comparable across age groups. TNFi-treated patients exhibited shorter disease duration, higher proportions of patients with Steinbrocker's stage I and II RA and biologics-naïve patients, higher MTX usage, and lower pre-existing lung disease prevalence than ABA- and TCZ-treated patients. ABA-treated patients showed longer disease duration, higher proportion of patients with Steinbrocker’s stage III and IV RA, and higher pre-existing lung disease prevalence than those treated with other bDMARDs. TCZ-treated exhibited lower MTX usage, higher GC usage, higher CRP and ESR levels, and higher CDAI scores than those treated with other bDMARDs.

Three-year retention rates of bDMARDs in all patients and by age group are shown in Additional file 1: Figure S2 and Fig. 1. No significance test was performed because the data were non-adjusted. The three-year retention rate of bDMARDs was 48.9% in all patients (Additional file 1: Figure S2A), 48.6% in patients aged <65 years, 48.9% in patients aged 65–74 years, and 50.6% in patients aged ≥75 years (Additional file 1: Figure S2B). Three-year retention rates of TNFi, ABA, and TCZ were 42.6%, 55.4%, and 64.8%, respectively, in all patients (Fig. 1A). Three-year retention rates in patients aged <65, 65–74, and ≥75 years were 43.1%, 43.2%, and 39.7%, respectively, for TNFi; 52.5%, 54.0%, and 62.9%, respectively, for ABA; and 67.0%, 63.9%, and 58.1%, respectively, for TCZ (Fig. 1B, 1C, and 1D).

**Risk factors for bDMARD discontinuation in non-adjusted data.** In all patients, the risk factors for drug discontinuation included age (hazard ratio [HR] = 0.992, 95% confidence interval [CI] = 0.986–0.999), female gender (HR = 0.672, 95% CI = 0.554–0.821), HAQ-DI (HR = 1.135, 95% CI = 1.013–1.272), TNFi versus ABA usage (HR = 1.301, 95% CI = 1.065–1.600), TNFi versus TCZ usage (HR = 1.919, 95% CI = 1.475–2.542), and ABA versus TCZ usage (HR = 1.474, 95% CI = 1.085–2.024) (Additional file 1: Table S4). We checked the proportional hazards assumption using the Schoenfeld residuals, and the proportional hazards assumption met the requirements of the Cox proportional hazards model. Each bDMARD was a risk factor for drug discontinuation. The results suggest that discontinuation was related to the mechanism of action of bDMARDs (TNF blockade, IL-6 blockade, or adjustment of CD28:CD80/86 costimulatory signal) and AEs.

**Retention rates of bDMARDs in adjusted data.** Next, we focused on differences in drug retention between age-related groups. Although non-adjusted data analyses suggested great differences in drug retention rates across bDMARD type, the retention rates were affected by patient selection bias or confounding by indication. Thus, they were minimized by applying IPTW based on generalized propensity score, and the retention rate of each bDMARD was compared among the age groups (Fig. 2). Differences in baseline characteristics were adjusted by IPTW (Additional file 1: Table S5). In all patients, three-year retention rates of TNFi, ABA, and TCZ were 43%, 51%, and 65%, respectively. The retention rate of TCZ was significantly higher than rates of ABA and TNFi (ABA versus TCZ, p = 0.021; TNFi versus TCZ, p < 0.001; Fig. 2A). In patients aged <65 years, three-year retention rates of TNFi, ABA, and TCZ were 43%, 47%, and 69%, respectively. The retention rate of TCZ was significantly higher than rates of ABA and TNFi (ABA versus TCZ, p = 0.017; TNFi versus TCZ, p = 0.002; Fig. 2B). In patients aged 65–74 years, three-year retention rates of TNFi, ABA, and TCZ were 44%, 53%, and 60%, respectively. The retention rate of TCZ was significantly higher than that for
TNFi ($p = 0.034$; Fig. 2C). In patients aged $\geq 75$ years, three-year retention rates for TNFi, ABA, and TCZ were 38%, 63%, and 58%, respectively. The retention rate of ABA was significantly higher than that of TNFi ($p = 0.017$; Fig. 2D). No statistical analysis was performed for TCZ usage data because of the small sample size. Overall, retention rates of TCZ were higher in patients aged <65 and 65–74 years, and retention rates of ABA increased with age.

**Reasons for bDMARD discontinuation in non-adjusted data.** Reasons for the discontinuation of each bDMARD were analyzed by age (Table 3 and Additional file 1: Table S6). In patients aged <65 years, discontinuation because of remission was more frequent following treatment with TNFi (16.9%) and less frequent following treatment with TCZ (3.4%). The prevalence of effect insufficiency was higher following treatment with ABA (22.0%) and comparable between treatments with TNFi (14.5%) and TCZ (15.5%). AE incidence was lower following treatment with ABA (4.9%). Particularly, there was no incidence of skin and subcutaneous tissue disorders. Similarly, in patients aged 65–74 years, discontinuation because of remission was more frequent following treatment with TNFi (10.5%) and the prevalence of effect insufficiency was lower following treatment with TCZ (8.5%). AE incidence was comparable among the three drugs. Likewise, in patients aged $\geq 75$ years, discontinuation because of remission was more frequent following treatment with TNFi (9.9%). The prevalence of effect insufficiency was comparable among the three drugs, and AE incidence was lower following treatment with TCZ (6.9%) and ABA (4.3%). Among AEs, the incidence of infections was lower following treatment with ABA. Overall, the rate of discontinuation because of remission was higher following treatment with TNFi and AE incidence was lower following treatment with ABA in all age groups.

**Retention rates of bDMARDs in adjusted data after excluding patients who discontinued treatment because of remission.** Among the reasons for bDMARD discontinuation, the rate of discontinuation because of remission was higher following treatment with TNFi in each age group. Thus, patients who discontinued treatment because of remission were excluded from the analysis. The background characteristics of the remaining patients according to age and bDMARD usage are presented in Additional file 1: Tables S7-10. Retention rates were analyzed (Additional file 1: Figure S3) after adjusting for differences in baseline characteristics using IPTW (Additional file 1: Table S11). In all patients, three-year retention rates of TNFi, ABA, and TCZ were 48%, 55%, and 69%, respectively. The retention rate of TCZ was significantly higher than rates of ABA and TNFi (ABA $\texttt{versus}$ TCZ, $p = 0.029$; TNFi $\texttt{versus}$ TCZ, $p = 0.001$; Additional file 1: Figure S3A). In patients aged <65 years, three-year retention rates of TNFi, ABA, and TCZ were 52%, 52%, and 73%, respectively. The retention rate of TCZ was significantly higher than rates for ABA and TNFi (ABA $\texttt{versus}$ TCZ, $p = 0.025$; TNFi $\texttt{versus}$ TCZ, $p = 0.011$; Additional file 1: Figure S3B). In patients aged 65–74 years, three-year retention rates of TNFi, ABA, and TCZ were 48%, 55%, and 63%, respectively. The retention rate of TCZ was significantly higher than that of TNFi ($p = 0.048$; Additional file 1: Figure S3C). In patients aged $\geq 75$ years, three-year retention rates of TNFi, ABA, and TCZ were 42%, 65%, and 63%, respectively. The retention rate of ABA was significantly higher than that of TNFi ($p = 0.019$; Additional file 1: Figure S3D). No statistical analysis was performed for TCZ data because of the small sample size. Overall, similar results to those shown in Fig. 2 were obtained even after patients who discontinued treatment because of remission were excluded.

**Changes in disease activity in non-adjusted and adjusted data.** Changes in CDAI were analyzed to evaluate the effects of bDMARDs. First, non-adjusted data analysis was performed to analyze CDAI at baseline and 1, 2, and 3 years (Additional file 1: Figure S4). In all patients and in each age group, CDAI tended to change in a similar manner among patients treated with TNFi, ABA, and TCZ (Additional file 1: Figure S4A, B, C, and D). Disease activity remained low in many patients who continued treatment, regardless of the bDMARD type. Furthermore, changes in CDAI from baseline to 1, 2, and 3 years were analyzed using IPTW based on generalized propensity scores (Fig. 3). In all patients, the greatest improvement in CDAI was observed with TNFi treatment, with mean differences of $-12.2$ (95% CI = $-13.5$ to $-10.9$) at 1, $-12.3$ (95% CI = $-14.2$ to $-10.5$) at 2, and $-13.6$ (95% CI = $-15.9$ to $-11.2$) at 3 years (Fig. 3A). Patients
aged <65 years showed the greatest improvement in CDAI following TNFi treatment, with a mean difference of −12.9 (95% CI = −14.5 to −11.3) at 1 year (Fig. 3B). Conversely, in the remaining age groups, there were no significant differences in the degree of CDAI improvement following TNFi, ABA, or TCZ treatment (Fig. 3C and D). In patients aged 65–74 and ≥75 years (Fig. 3C and D), differences in CDAI at 1 year were −11.5 (95% CI = −14.0 to −9.0) and −11.6 (95% CI = −15.5 to −7.7), respectively, for TNFi, −4.7 (95% CI: −9.7 to 0.2) and −6.4 (95% CI = −10.9 to −2.0), respectively, for ABA, and −3.1 (95% CI = −8.9 to 2.6) and −3.8 (95% CI = −14.6 to 6.9), respectively, for TCZ. For TCZ, because of the small sample size, the 95% CIs for changes in CDAI at 2 and 3 years were wide, particularly in the older age groups, and the results for this drug should only be used as a reference.

Discussion

In this study, after reducing selection bias and confounding by indication by applying IPTW based on generalized propensity score, the long-term retention rates of bDMARDs were examined by age group in actual clinical practice. Consequently, the following two novel points were revealed. First, in all age groups, the highest retention rate was observed for TCZ. Second, in patients aged ≥65 years (particularly those aged ≥75 years), the retention rates of ABA and TCZ were similar. Moreover, secondary assessment revealed the following two points. First, in all age groups, the lowest rate of discontinuation because of AEs was observed with ABA. Second, TNFi treatment improved disease activity more effectively and was associated with the highest rate of discontinuation because of clinical remission in all age groups.

In the analysis of “Retention rates of bDMARDs in non-adjusted data,” the retention rate was affected by patient selection bias and confounding by indication. Therefore, we used IPTW based on generalized propensity score to minimize the selection bias and confounding. The patient selection bias and confounding by indication are represented by the differences in patient background at baseline among the bDMARD groups. The results suggest that the physicians might have selected patients based on the following characteristics of each bDMARD therapy. TNFi therapy in combination with MTX is effective and may lead to discontinuation because of remission in patients with early RA [25-31]. ABA therapy is considered one of the bDMARDs that are potentially applicable to patients with infection risk and those with interstitial lung disease, according to previous studies, including the all-case postmarketing surveillance of bDMARDs in Japan [32, 33]. TCZ therapy has an advantage over other bDMARDs in the treatment of patients who cannot be treated with csDMARDs [3] and those with high CRP (as TCZ inhibits IL-6) [34]. Comorbidities are also important considerations in drug selection. Among the comorbidities, this study focused on pre-existing lung diseases. Chronic obstructive pulmonary disease and interstitial lung disease are associated with an increased risk of the development of serious infection in patients with RA receiving TNFi therapy [35]. In addition, it is considered that TNFi should be carefully selected for patients with poor respiratory reserve [33]. In contrast, it is suggested that ABA therapy has lesser adverse effects on interstitial lung disease than other bDMARDs [36].

In this study, the retention rate of TCZ was high in all age groups, particularly in patients aged <65 years, and remained high in those aged ≥65 years. In a meta-analysis of studies on RA, TCZ and MTX combination was identified as the best intervention [37]. TCZ showed higher retention rates than TNFi and ABA in other studies [38, 39], which supports the results of this study. It is also reported that elderly patients with RA have higher disease activity at baseline and higher CRP level owing to age-related increases in inflammation; thus, IL-6 inhibitors may be suitable for elderly patients with RA [34, 40, 41]. The retention rates of ABA and TCZ were similar in patients aged ≥65 years, and this similarity more pronounced in those aged ≥75 years. As a possible explanation for these findings, it is important that ABA showed the lowest discontinuation rate because of AEs in all age groups in this study and that the degree of improvement in disease activity was comparable among the drugs in patients aged ≥75 years. Regarding safety and age, an all-case postmarketing surveillance of bDMARDs in Japan revealed that age (≥65 years) contributed to severe
infection onset with all biopharmaceuticals except for ABA [32, 42-45]. Long-term safety of ABA [46, 47] has been reported, and guidelines of the British Society for Rheumatology recommend ABA as the first-line treatment for patients at a risk of infection [33]. The efficacy of ABA is similar to that of TNFi [48, 49] and TCZ [50]. Regarding the effects of TNFi, there is insufficient evidence to compare retention rates between TNFi and the other bDMARDs. However, a few studies reported that the retention rate of ETN was higher than that of IFX and ADA [51, 52] and that the retention rate of IFX was lower than that of ETN and ADA [51, 53].

Elderly RA patients often present higher disease activity and greater functional impairment than young patients [34]. In recent years, immunosenescence has attracted much attention, and risk of inflammation and autoimmune diseases increases with age [54]. Immunosenesescence is characterized by the lack of CD28 in T-cells [54], and CD28-negative T-cell count increases with age [55]. Lack of CD28 in CD4-positive T-cells is associated with chronic autoimmune diseases, including RA [54]. ABA therapy reduces CD28-negative CD4-positive T-cell counts, and this reduction in CD28-negative T-cell count is associated with the responsiveness of RA as assessed by DAS28 based on CRP level [56, 57]. Thus, ABA may be suitable for improving immune dysregulation in elderly RA patients. However, previous studies at our institution as well as others reported that high CD28-negative CD4-positive T-cell count increases the risk of decreased responsiveness to ABA therapy [58], and the responsiveness to ABA therapy improves with decreasing pretreatment CD28-negative T-cell count [59]. That is, some elderly people may be at a risk of acquiring treatment resistance because of increasing CD28-negative T-cell count with increasing age. These previous studies suggest that heterogeneity increases in elderly RA patients. Thus, drug selection based on both safety and treatment responsiveness is preferable.

In terms of disease activity, non-adjusted data analysis demonstrated that the degree of improvement was comparable among the three bDMARDs, although adjusted data analysis identified differences in the degree of improvement among TNFi, ABA, and TCZ. These differences suggested that patient selection bias, as indicated by differences in patient characteristics in the non-adjusted data, maximized the effect of each bDMARD in actual clinical practice. In adjusted data analysis, the improvement achieved with TNFi was greater in all age groups, and this effect was especially pronounced in patients aged <65 years. The Remission Induction by Remicade in RA (RRR) study using IFX at our institution [26], the Humira Discontinuation without Functional and Radiographic Damage Progression following Sustained Remission (HONOR) study using ADA at our institution [27, 28], and other studies [29-31] reported that TNFi therapy may lead to discontinuation because of remission. Early-stage RA was also identified as highly reliable predictors of successful bDMARD tapering [3]. Although TNFi showed the lowest retention rate among the three bDMARDs groups, future studies are warranted to reveal characteristics of patient populations in which TNFi use is preferred and can achieve discontinuation because of remission.

This study has some limitations. First, the data were obtained from routine clinical practice, and no clear criteria were set for bDMARD discontinuation, with the decision being left at the attending physician's discretion. Second, because IPTW based on generalized propensity score cannot exclude the effects of unknown confounding factors, this study may not have sufficiently eliminated biases compared with randomized controlled trials. Third, because IFX, ETN, ADA, GLM, and CZP were analyzed collectively as TNFi, the characteristics of each TNFi may not have been reflected.

Fourth, the sample size of patients treated with TCZ was small; thus, the retention rate of TCZ among patients aged ≥75 years and changes in CDAI at 2 and 3 years with TCZ therapy in patients aged 65–74 and ≥75 years could only be used as a reference. Fifth, this study focused on the elderly population and did not perform subgroup analysis of the younger population aged less than 65 years. Sixth, history of bDMARD use may affect the retention rate of bDMARDs. However, in this study, we were unable to perform statistical analysis of subgroups, such as those treated with first-line bDMARDs and those treated with second-line or later bDMARDs, owing to the insufficient sample size. Seventh, although the emergence of new clinical evidence and new treatment options can lead to changes in the
prescription practice of physicians, we could not sufficiently adjust some variables such as the calendar time of starting bDMARDs or drug approval time. Finally, this study did not include any Janus kinase inhibitors, the use of which will increase in the future.

**Conclusions**

Despite the limitations, in this study, we found that the effectiveness and safety of TCZ were maximal in patients aged <75 years and that patients aged ≥75 years might be suitable candidates for TCZ and ABA therapy. Furthermore, in patients aged <65 years, TNFi improved disease activity more effectively and was associated with increased frequently of discontinuation because of remission. Finally, the use of therapeutic strategies appropriate to each age group might improve the outcomes of bDMARD therapy for RA.

**Abbreviations**

RA: Rheumatoid arthritis

MTX: Methotrexate

bDMARDs: Biological disease-modifying antirheumatic drugs

ADL: Activities of daily living

AEs: Adverse events

IPTW: Inverse probability of treatment weighting

TNFi: Tumor necrosis factor inhibitors

IFX: Infliximab

ETN: Etanercept

ADA: Adalimumab

GLM: Golimumab

CZP: Certolizumab pegol

ABA: Abatacept

TCZ: Tocilizumab

csDMARDs: Conventional synthetic disease-modifying antirheumatic drugs

DAS28: Disease activity score using 28 joint counts

CDAI: Clinical disease activity index

SDAI: Simple or simplified disease activity index

GC: Glucocorticoid
HAQ-DI: Health Assessment Questionnaire-Disability Index

CRP: C-reactive protein

ESR: Erythrocyte sedimentation rate

RF: Rheumatoid factor

HR: Hazard ratio

CI: Confidence interval

Declarations

Ethics approval and consent to participate. This study was approved by the ethics review board of the University of Occupational and Environmental Health, Japan, and written informed consent was waived because of the retrospective study design.

Consent for publication. Not applicable.

Availability of data and materials. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests. AK has received speaking fees and/or honoraria from Bristol-Myers and Janssen (less than $10,000 each). KN has received speaking fees and/or honoraria from Bristol-Myers, Sanofi, AbbVie, Eisai, Eli Lilly, Chugai, Pfizer, Takeda, and Mitsubishi-Tanabe (less than $10,000 each), and research grants from Mitsubishi-Tanabe and Eisai. SK has received speaking fees and/or honoraria from Eli Lilly, Bristol-Myers, Pfizer, and Takeda (less than $10,000 each). TA declare no conflict of interest. YT has received speaking fees and/or honoraria from Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, Eli Lilly, Abbvie (more than $10,000 each), UCB, YL Biologics, Takeda, Eisai, Novartis, Janssen, and Teijin (less than $10,000 each), and research grants from Asahi-kasei, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai, and Ono.

Funding. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Authors’ contributions. AK, KN, and YT contributed to the study conception and design. AK, KN, SK, and YT contributed to the acquisition of data. AK, KN, SK, TA, and YT contributed to the analysis and interpretation of data. All authors drafted the article or revising it critically for important intellectual content and approved of the final version of the article to be published.

Acknowledgements. The authors thank all the medical staff at our institution for providing the data. We also thank Yoshihisa Fujino, MD, PhD, MPH (Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan) for valuable comments to this work.

References

1. Statistics Bureau, Ministry of Internal Affairs and Communications Japan: Statistical Handbook of Japan 2018. https://www.stat.go.jp/english/data/handbook/pdf/2018all.pdf. Accessed 7 November 2018.
2. Ouchi Y, Rakugi H, Arai H, Akishita M, Ito H, Toba K, et al. Redefining the elderly as aged 75 years and older: Proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol Int. 2017;17:1045-7.

3. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960-77.

4. Rothschild JM, Bates DW, Leape LL. Preventable medical injuries in older patients. Arch Intern Med. 2000;160:2717-28.

5. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74:354-60.

6. Pers YM, Schaub R, Constant E, Lambert J, Godfrin-Valnet M, Fortunet C, et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2015;82:25-30.

7. Cho SK, Sung YK, Kim D, Won S, Choi CB, Kim TH, et al. Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016;17:333.

8. Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38:90-6.

9. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika. 2000;87:706-10.

10. Sugihara M. Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score. Pharm Stat. 2010;9:21-34.

11. World Health Organization: Health statistics and information systems https://www.who.int/healthinfo/survey/ageingdefnolder/en/. Accessed 11 April 2020.

12. Zizza CA, Ellison KJ, Wernette CM. Total water intakes of community-living middle-old and oldest-old adults. J Gerontol A Biol Sci Med Sci. 2009;64:481-6.

13. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-56.

14. Shimada H, Makizako H, Doi T, Yoshida D, Tsutsumimoto K, Anan Y, et al. Combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people. J Am Med Dir Assoc. 2013;14:518-24.

15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.

16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.

17. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580-8.

18. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64:640-7.

19. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407-9.
20. US Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 15 September 2019.

21. Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507-12.

22. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796-806.

23. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100-8.

24. Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part III. Value Health. 2009;12:1062-73.

25. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68:1-26.

26. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69:1286-91.

27. Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. 2013;15:R135.

28. Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74:389-95.

29. Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Hiramatsu K, et al. Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study. RMD Open. 2016;2:e000189.

30. Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, et al. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis. 2017;76:1348-56.

31. Yamanaka H, Nagaoka S, Lee SK, Bae SC, Kasama T, Kobayashi H, et al. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Mod Rheumatol. 2016;26:651-61.

32. Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26:491-8.

33. Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford). 2018; doi:10.1093/rheumatology/key208.
34. Ishchenko A, Lories RJ. Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance. Drugs Aging. 2016;33:387-98.
35. Cobo-Ibanez T, Descalzo MA, Loza-Santamaria E, Carmona L, Munoz-Fernandez S. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int. 2014;34:953-61.
36. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43:613-26.
37. Cai W, Gu Y, Cui H, Cao Y, Wang X, Yao Y, et al. The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naive Rheumatoid Arthritis: A Network Meta-Analysis. Front Pharmacol. 2018;9:138.
38. Lauper K, Nordstrom DC, Pavelka K, Hernandez MV, Kvien TK, Kristianslund EK, et al. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis. 2018;77:1276-82.
39. Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. Bmj. 2019;364:l67.
40. Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. Rheumatology (Oxford). 2016;55:874-82.
41. Sugihara T, Harigai M. Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging. 2016;33:97-107.
42. Takeuchi T, Tatsuki Y, Nomami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-94.
43. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:343-51.
44. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24:390-8.
45. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41:15-23.
46. Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol. 2014;66:1987-97.
47. Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol. 2012;39:1546-54.
48. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86-94.
49. Kubo S, Nakayamada S, Nakano K, Sawamukai N, Hirata S, Hanami K, et al. Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. Clin
50. Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, et al. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis. 2016;75:1321-7.

51. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32.

52. Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55:523-34.

53. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560-8.

54. Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:604-13.

55. Fagnoni FF, Vescovini R, Mazzola M, Bologna G, Nigro E, Lavagetto G, et al. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology. 1996;88:501-7.

56. Imberti L, Scarsi M, Zanotti C, Chiarini M, Bertoli D, Tincani A, et al. Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients. J Transl Med. 2015;13:12.

57. Scarsi M, Ziglioli T, Airo P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol. 2010;37:911-6.

58. Fukuyo S, Nakayamada S, Iwata S, Kubo S, Saito K, Tanaka Y. Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017;35:562-70.

59. Scarsi M, Ziglioli T, Airo P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2105-11.

Tables

Table 1. Baseline characteristics of the study population
|                        | All patients | <65 yr | 65–74 yr | ≥75 yr | p     |
|------------------------|--------------|--------|----------|--------|-------|
| **N**                  | 1,362        | 695    | 402      | 265    |       |
| **Age (yr)**           |              |        |          |        | <0.001|
|                        | 64 (54–72)   | 54 (44–60) | 69 (67–72) | 79 (76–81) |       |
| **Gender (female) (%)**|              |        |          |        | 0.227 |
|                        | 81.6         | 83.3   | 79.4     | 80.4   |       |
| **Disease duration (yr)**|            |        |          |        | <0.001|
|                        | 4 (1–11)     | 3 (0.8–9) | 6 (1.4–15) | 5 (1.2–15) |       |
| **Stage (I + II) (%)** |              |        |          |        | <0.001|
|                        | 68.2         | 76.0   | 61.7     | 57.8   |       |
| **TNFi/ABA/TCZ (%)**   |              |        |          |        | <0.001|
|                        | 59.2/25.8/15.0 | 65.6/17.7/16.7 | 57/28.4/14.7 | 45.7/43.4/10.9 |       |
| **Bio-naïve (%)**      |              |        |          |        | 0.442 |
|                        | 74.1         | 75.4   | 71.9     | 74     |       |
| **MTX use (%)**        |              |        |          |        | <0.001|
|                        | 77.8         | 85.3   | 72.9     | 65.3   |       |
| **MTX dose (mg/w)**    |              |        |          |        | <0.001|
|                        | 14 (10–16)   | 14 (10–16) | 12(10–16) | 12 (8–16) |       |
| **GC use (%)**         |              |        |          |        | 0.001 |
|                        | 21.2         | 17.3   | 24.4     | 26.8   |       |
| **GC dose (mg/d)**     |              |        |          |        | 0.157 |
|                        | 5 (2.5–7.5)  | 4 (2.5–5) | 5 (2.5–9.3) | 5 (2.5–7.5) |       |
| **CRP (mg/dL)**        |              |        |          |        | <0.001|
|                        | 1.0 (0.2–3.0)| 0.6 (0.1–2.2) | 1.3 (0.3–3.2) | 1.5 (0.4–4.2) |       |
| **ESR (mm/h)**         |              |        |          |        | <0.001|
|                        | 47 (24–75)   | 35 (17–62) | 58 (32–80) | 66 (38–85) |       |
| **RF (IU/mL)**         |              |        |          |        | <0.001|
|                        | 60 (18–167)  | 45 (14–130) | 67 (23–188) | 105 (28–215) |       |
| **ACPA positive (%)**  |              |        |          |        | 0.026 |
|                        | 73.3         | 70.1   | 77.1     | 75.8   |       |
| **TJC, 0–28**          |              |        |          |        | 0.062 |
|                        | 7 (4–12)     | 7 (3–12) | 7 (3–12) | 8 (4–13) |       |
| **SJC, 0–28**          |              |        |          |        | 0.001 |
|                        | 6 (3–10)     | 6 (3–9) | 6 (3–10) | 7 (4–11) |       |
| **PGA, 0–100 mm**      |              |        |          |        | 0.002 |
|                        | 52 (35–72)   | 51 (32–71) | 51 (35–70) | 57 (42–76) |       |
| **EGA, 0–100 mm**      |              |        |          |        | <0.001|
|                        | 43 (29–58)   | 40 (26–55) | 43 (30–57) | 49 (34–62) |       |
| **CDAI**               |              |        |          |        | <0.001|
|                        | 24 (16–32)   | 23 (15–31) | 24 (16–34) | 27 (20–35) |       |
| **HAQ-DI**             |              |        |          |        | <0.001|
|                        | 1.3 (0.6–2.0) | 1 (0.4–1.6) | 1.3 (0.6–2) | 1.9 (1.3–2.5) |       |
| **Pre-existing lung disease (%)** |           |        |          |        | <0.001|
|                        | 27.4         | 18.4   | 32.3     | 43.4   |       |

Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker’s stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint.
count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.

**Table 2. Baseline characteristics of patients treated with bDMARDs**

|               | TNFi   | ABA     | TCZ     | p      |
|---------------|--------|---------|---------|--------|
| N             | 806    | 352     | 204     |        |
| Age (yr)      | 62 (51–71) | 68 (60–76) | 63 (54–70) | <0.001 |
| <65/65–74/≥75 yr (%) | 56.6/28.4/15 | 34.9/32.4/32.7 | 56.9/28.9/14.2 | <0.001 |
| Gender (female) (%) | 79.9 | 85.5 | 81.4 | 0.077 |
| Disease duration (yr) | 3 (0.8–9) | 7 (2–16) | 5 (1.3–12) | <0.001 |
| Stage (I + II) (%) | 74.1 | 56.3 | 65.7 | <0.001 |
| Bio-naïve (%) | 80.1 | 63.6 | 68.1 | <0.001 |
| MTX use (%)   | 87.5   | 66.5   | 58.8   | <0.001 |
| MTX dose (mg/w) | 14 (10–16) | 12 (8–16) | 12 (8–16) | <0.001 |
| GC use (%)    | 17.6   | 24.4   | 29.9   | <0.001 |
| GC dose (mg/d) | 4.5 (2.5–6.3) | 4.5 (2.5–8) | 5 (2.5–7.8) | 0.672 |
| CRP (mg/dL)   | 0.8 (0.2–3) | 0.7 (0.1–2) | 2.3 (0.7–5.3) | <0.001 |
| ESR (mm/h)    | 43 (20–73) | 44 (24–71) | 63 (40–85) | <0.001 |
| RF (IU/mL)    | 52 (16–151) | 78 (25–199) | 72 (19–161) | 0.003 |
| ACPA positive (%) | 72.5 | 76.1 | 71.6 | 0.274 |
| TJC, 0–28     | 7 (4–12) | 6 (3–12) | 8 (4–13) | 0.008 |
| SJC, 0–28     | 6 (3–10) | 6 (2–9) | 7 (4–11) | 0.001 |
| PGA, 0–100 (mm) | 52 (35–71) | 50 (33–71) | 55 (38–75) | 0.168 |
| EGA, 0–100 (mm) | 45 (30–60) | 40 (25–52) | 43 (31–59) | 0.002 |
| CDAI          | 24 (16–32) | 22 (15–31) | 26 (18–35) | 0.001 |
| HAQ-DI        | 1.1 (0.5–1.9) | 1.4 (0.6–2.1) | 1.4 (0.8–2.1) | 0.004 |
| Pre-existing lung disease (%) | 22.5 | 39.8 | 25.5 | <0.001 |
Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker’s stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.

Table 3. Reasons for discontinuation of bDMARDs in non-adjusted data

|                  | <65 yr | 65–74 yr | ≥75 yr |
|------------------|--------|----------|-------|
|                  | TNFi   | ABA      | TCZ   | TNFi | ABA | TCZ | TNFi | ABA | TCZ |
| N                | 456    | 123      | 116   | 229  | 114 | 59  | 121  | 115 | 29  |
| Remission        | 77     | 9        | 4     | 24   | 4   | 3   | 12   | 4   | 1   |
|                  | (16.9) | (7.3)    | (3.4) | (10.5)| (3.5)| (5.1)| (9.9) | (3.5)| (3.4)|
| Effect insufficiency | 66      | 27       | 18    | 53   | 23  | 5   | 22   | 22  | 5   |
|                  | (14.5) | (22.0)   | (15.5)| (23.1)| (20.2)| (8.5)| (18.2)| (19.1)| (17.2)|
| Adverse events   | 43     | 6        | 10    | 29   | 12  | 8   | 22   | 5   | 2   |
|                  | (9.4)  | (4.9)    | (8.6) | (12.7)| (10.5)| (13.6)| (18.2)| (4.3)| (6.9)|
| Others           | 44     | 8        | 2     | 15   | 3   | 1   | 4    | 5   | 1   |
|                  | (9.6)  | (6.5)    | (1.7) | (6.6)  | (2.6) | (1.7) | (3.3) | (4.3) | (3.4)|

Values are the number (%). yr = years; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab.
Table S3. Baseline characteristics of patients aged ≥75 years treated with bDMARDs

Table S4. Risk factors for the discontinuation of bDMARDs in all patients

Table S5. The generalized propensity score model in all patients

Table S6. Adverse events responsible for the discontinuation of bDMARDs in non-adjusted data

Table S7. Baseline characteristics of bDMARD groups after excluding patients who discontinued treatment because of remission

Table S8. Baseline characteristics of patients <65 years of age treated with bDMARDs after excluding patients who discontinued treatment because of remission

Table S9. Baseline characteristics of patients 65–74 years of age treated with bDMARDs after excluding patients who discontinued treatment because of remission

Table S10. Baseline characteristics of patients ≥75 years of age treated with bDMARDs after excluding patients who discontinued treatment because of remission

Table S11. Assessment of the generalized propensity score model after excluding patients who discontinued treatment because of remission

Figure S1. Flow chart of patient recruitment

Figure S2. Three-year retention rates of bDMARDs in non-adjusted data

Figure S3. Three-year retention rates of bDMARDs in adjusted data using inverse probability of treatment weighting after excluding patients who discontinued treatment because of remission

Figure S4. Changes in CDAI in non-adjusted data

Description of data:

Table S1. Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker's stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.

Table S2. Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker's stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.
Table S3. Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker's stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.

Table S4. The Cox proportional hazards model was used to assess risk factors for discontinuation. Age and variables with \( p < 0.1 \) in univariate analysis (the log-rank test) were adopted for multivariate analysis. In univariate analysis, median was used to split continuous variables into groups. 95% CI = 95% confidence interval; Stage = Steinbrocker's stages; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index; bDMARDs = biological disease-modifying antirheumatic drugs; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab.

Table S5. Mann–Whitney U test, t-test, or tests for two independent proportions were used. AUC = area under the curve; IPTW = inverse probability of treatment weighting; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; bDMARD = biological disease-modifying antirheumatic drug; MTX = methotrexate; GC = glucocorticoid; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor.

Table S6. Values are the number (%). yr = years; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab.

Table S7. Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker's stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.

Table S8. Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker's stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.

Table S9. Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker's stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale;
EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.

Table S10. Values are the median (interquartile range) unless indicated otherwise. Kruskal–Wallis and chi-square tests were used. yr = years; w = week; d = day; Stage = Steinbrocker’s stages; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; Bio-naïve = biologics-naïve patients; MTX = methotrexate; GC = glucocorticoid; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibody; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index.

Table S11. Mann–Whitney U test, \(t\)-test, or tests for two independent proportions were used. AUC = area under the curve; IPTW = inverse probability of treatment weighting; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab; bDMARD = biological disease-modifying antirheumatic drug; MTX = methotrexate; GC = glucocorticoid; TJC = tender joint count; SJC = swollen joint count; PGA = patient global assessment visual analogue scale; EGA = evaluator global assessment visual analogue scale; CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire-disability index; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor.

Figure S1. RA = rheumatoid arthritis; bDMARDs = biological disease-modifying antirheumatic drugs.

Figure S2. Three-year retention rates of bDMARDs in all patients (A) and by age groups (B). yr = years; No. at risk = number at risk.

Figure S3. Three-year retention rates of bDMARDs in all patients (A), in patients aged <65 years (B), patients aged 65–74 years (C), and patients aged ≥75 years (D). yr = years; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab.

Figure S4. Changes in CDAI in all patients (A), patients aged <65 years (B), patients aged 65–74 years (C), and patients aged ≥75 years (D). Last observation was carried forward to assess changes in CDAI. Data are presented as mean ± 95% confidence interval (error bars). CDAI = clinical disease activity index; yr = years; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab.

Figures
Figure 1

Three-year retention rates of bDMARDs by age group in non-adjusted data Three-year retention rates of bDMARDs in all patients (A), in patients aged <65 years (B), in patients aged 65–74 years (C), and in patients aged ≥75 years (D). yr = years; No. at risk = number at risk; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab.
Figure 2

Three-year retention rates of bDMARDs in adjusted data using inverse probability of treatment weighting. Three-year retention rates of bDMARDs in all patients (A), in patients aged <65 years (B), in patients aged 65–74 years (C), and in patients aged ≥75 years (D). yr = years; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab.
Figure 3

Changes in CDAI in adjusted data using inverse probability of treatment weighting. Changes in CDAI in all patients (A), patients aged <65 years (B), patients aged 65–74 years (C), and patients aged ≥75 years (D). Data are presented as mean ± 95% confidence interval (error bars). CDAI = clinical disease activity index; yr = years; TNFi = tumor necrosis factor inhibitors; ABA = abatacept; TCZ = tocilizumab.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.pdf